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Background: The extent to which long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from fish oil such
as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert their anti-inflammatory effects by down-
regulating intestinal inflammation in humans is unknown. We investigated the impact of LCn-3PUFA
supplementation on inflammatory gene expression in the duodenum of obese patients with type 2 diabetes.
Findings: This placebo-controlled randomized crossover study included 12 men with type 2 diabetes. After a
4-week run-in period, patients received in a random sequence 5 g/d of fish oil (providing 3 g of EPA + DHA) and a
placebo (corn and soybean oil) for 8 weeks each. The two treatment phases were separated by a 12-week washout
period. Gene expression was assessed by real-time polymerase chain reaction in duodenal biopsy samples obtained
in the fasted state at the end of each treatment phase. Intestinal mRNA expression levels of interleukin (IL)-6 and
tumor-necrosis factor (TNF)-α were hardly detectable after either treatment (<100 copies/105 copies of the
reference gene ATP5o). Intestinal mRNA expression of IL-18 and of the transcription factor signal transducer and
activator of transcription 3 (STAT3) was higher (>5000 copies/105 copies ATP5o) but still relatively low. EPA + DHA
supplementation had no impact on any of these levels (all P ≥ 0.73).
Conclusions: These data suggest that duodenal cells gene expression of pro-inflammatory cytokines is low in
patients with type 2 diabetes and not affected by EPA + DHA supplementation. Further studies are warranted to
determine if inflammatory gene expression in other tissues surrounding the intestine is modulated by EPA + DHA
supplementation.
Trial registration: ClinicalTrials.gov ID: NCT01449773
Keywords: Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), Signal transducer and activator of
transcription 3 (STAT3), Inflammatory gene expression, n-3 supplementation, Placebo-controlled, Duodenum, Type 2
diabetes* Correspondence: benoit.lamarche@fsaa.ulaval.ca
1Institute of Nutrition and Functional Foods, Laval University, 2440 boul.
Hochelaga, Québec (Qc) G1V 0A6, Canada
Full list of author information is available at the end of the article
© 2013 Labonté et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Labonté et al. Nutrition Journal 2013, 12:98 Page 2 of 5
http://www.nutritionj.com/content/12/1/98Findings
Introduction
It is widely recognized that obesity, metabolic syn-
drome, and type 2 diabetes are associated with low-
grade chronic inflammation [1], attributed in part to an
expanded adipose tissue mass infiltrated with macro-
phages that secrete pro-inflammatory cytokines [2,3]. It
has been suggested that diet-induced inflammation in
the small intestine is also linked to obesity and insulin
resistance [4]. Long-chain omega-3 polyunsaturated
fatty acids (LCn-3PUFA) such as eicosapentaenoic acid
(EPA, C20:5) and docosahexaenoic acid (DHA, C22:6)
have been shown to have anti-inflammatory effects by
down-regulating inflammatory gene expression in adi-
pocytes and mononuclear cells [5-7]. Intervention
studies evaluating the extent to which EPA and DHA
may exert their anti-inflammatory effects by down-
regulating intestinal inflammation are lacking. The aim
of the present study was to investigate the impact of
EPA and DHA supplementation on the expression of in-
flammatory genes in the duodenum of obese men with
type 2 diabetes, who are likely to have intestinal inflam-
mation [4] and therefore to respond favorably to LCn-
3PUFA supplementation [8]. We hypothesized that EPA
and DHA supplementation reduces pro-inflammatory
gene expression in the duodenum of obese men with
type 2 diabetes.Methods
Participants
Twelve adult men with type 2 diabetes were recruited
via the Lipid Clinic of the Laval University Hospital
Research Center, Québec, QC, Canada, between April
2008 and March 2009. Diagnosis of type 2 diabetes
was based on criteria issued by the American Diabetes
Association [9]. Inclusion criteria were: age between
18 and 55 y, plasma triglyceride (TG) levels above the
50th percentile for age [10], non-smoker, body mass
index (BMI) between 25.0 and 40.0 kg/m2, stable body
weight over the last 6 mo, hemoglobin A1c (HbA1c)
between 6.5 and 8.5%, baseline fasting plasma glucose
< 15.0 mmol/L and patients with de novo type 2 dia-
betes not taking oral hypoglycemic agents or patients
having received stable doses of metformin for at least
3 mo before randomization. Exclusion criteria were:
genetic dyslipidemias, patients with secondary form of
diabetes or acute metabolic diabetic complications,
subjects having cardiovascular diseases or taking me-
dication known to affect lipoprotein metabolism (e.g.
lipid lowering agents). All participants signed an
informed consent document approved by the Ethics
Board of the Laval University Hospital Research
Center.Study design
The study was undertaken according to a double-blind
randomized crossover design with two balanced [1:1]
treatments of 8 weeks each. All subjects received, in ran-
dom order: 5 g/d (5 × 1 g capsules) of fish oil providing
3 g/d of EPA (64%) and DHA (36%) or a control sup-
plementation (5 × 1 g capsules/d of a 50/50 blend of
corn and soybean oil). Treatments were separated by a
12-week washout. During a 4-week run-in stabilization
period that preceded the treatments, participants were
advised to consume a low fat diet following the recom-
mendations of the National Cholesterol Education Pro-
gram - Adult Treatment Panel III [11]. Dietary intake of
marine-derived LCn-3PUFA was limited by prohibiting
the consumption of fish during the entire experimental
period, including the washout period. Alcohol consump-
tion, vitamin supplements and natural health products
were also strictly forbidden during the entire experimen-
tal period.
Participants’ baseline intake of marine-derived LCn-
3PUFA was assessed using a validated interviewer-ad-
ministered food frequency questionnaire [12]. Compliance to
supplementation was assessed by counting the number of
capsules returned to the research staff over the course of the
experimentation.
Characterization of plasma lipids
Plasma TG concentrations were determined by enzym-
atic methods at the end of each supplementation period
using the Technicon RA-1000 analyzer (Technicon In-
struments Corporation, Tarrytown, NY). Plasma phos-
pholipids fatty acid levels were determined as previously
described [13].
Duodenal biopsies
Four biopsy samples (3 × 3 mm) were obtained at the
end of each phase by gastro-duodenoscopy from the sec-
ond portion of the duodenum using multiple sample
single-use biopsy forceps and were immediately flash-
frozen in liquid nitrogen and stored at −80°C, as previ-
ously described [14].
Total RNA extraction
Biopsy samples were homogenized in 1 ml of Qiazol.
Ribonucleic acid (RNA) was then extracted using an
RNeasy mini-kit (Qiagen). Tissue samples were also
treated with an RNase-free DNase set to eliminate any
contaminant deoxyribonucleic acid (DNA). Total RNA
was then eluted into 100 μl RNase-free H2O and stored
at −80°C.
RNA quantification and quantitative real-time PCR
Details on RNA quantification and quantitative real-time
PCR are provided in Additional file 1. Briefly, RNA
Table 2 Plasma phospholipids fatty acid levels after EPA
+ DHA and placebo supplementation in 12 men with
type 2 diabetes
Placebo EPA + DHA
Difference P
Fatty acid levels (%)
LA 19.9 (3.6) 19.3 (2.9) −0.6 0.09
ALA 0.21 (0.09) 0.19 (0.11) −0.02 0.85
DGLA 3.82 (1.57) 2.87 (0.65) −0.95 0.001
AA 9.40 (2.05) 7.97 (1.37) −1.43 0.0005
EPA 1.00 (0.93) 3.53 (1.65) 2.53 0.0005
DPA 1.03 (0.34) 1.25 (0.26) 0.22 0.0005
DHA 2.96 (1.15) 4.43 (1.26) 1.47 0.0005
Data are expressed as median and interquartile range in parentheses. P values
were calculated using Wilcoxon matched-pairs signed-rank tests.
Abbreviations: AA, arachidonic acid; ALA, alpha-linolenic acid; DGLA, dihomo-γ-
linoleic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA,
eicosapentaenoic acid; LA, linoleic acid; PUFA, polyunsaturated fatty acids.
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Technologies, Inc.) as previously described [15]. Messen-
ger RNA (mRNA) expression data were normalized
using the second derivative and double correction
method [16] and are expressed as the number of copies/
105 copies of the reference gene ATP synthase O subunit
(ATP5o). The standard curve was established by using
known amounts of purified polymerase chain reaction
products and the Light Cycler 480 version 1.5 software
provided by the manufacturer (Roche Inc).
Statistical analyses
Nonparametric Wilcoxon matched-pairs signed-rank
tests were used to compare the impact of LCn-3PUFA
and placebo on inflammatory gene mRNA expression in
duodenal tissues. Mixed models with proper interaction
terms have shown no evidence of a carry-over effect of
the LCn-3PUFA supplementation (not shown). Associa-
tions among key outcomes were assessed using Spearman
correlation coefficients. Differences were considered sig-
nificant at P < 0.05. Analyses were performed using SAS
(version 10.1; SAS Institute, Cary, NC).
Results
All 12 recruited participants completed the study and
were included in the analyses. Table 1 shows their char-
acteristics. Body weight remained stable throughout the
study. More than 80% of the capsules were taken by par-
ticipants. No side effects were reported. Plasma phos-
pholipids LCn-3PUFA levels were higher while plasma
phospholipids levels of dihomo-γ-linoleic acid and ara-
chidonic acid were lower after EPA + DHA supplemen-
tation than after placebo (all P ≤ 0.001). This again
reflected good compliance. There was no between-
treatment difference in alpha-linolenic acid and linoleic
acid levels (both P ≥ 0.09, Table 2). Mean plasma TG
concentrations tended to be lower after EPA + DHA
supplementation than after placebo (2.30 ± 1.09 vs. 2.50 ±
1.22 mmol/L; P = 0.08).Table 1 Characteristics of the study participants at
screening (n = 12 men with type 2 diabetes)
Mean ± SD
Age (y) 54.1 ± 7.2
BMI (kg/m2) 33.7 ± 6.0
LDL-C (mmol/L) 2.9 ± 0.5
HDL-C (mmol/L) 1.0± 0.2
TG (mmol/L) 3.1 ± 2.0
HbA1c (%) 7.0 ± 0.8
EPA + DHA intake (g/d) 0.23 ± 0.20
Abbreviations: BMI body mass index, DHA docosahexaenoic acid, EPA
eicosapentaenoic acid, HbA1c hemoglobin A1c, HDL-C high density lipoprotein
cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides.Table 3 presents the duodenal mRNA expression of in-
flammatory genes measured after placebo and EPA +
DHA treatments. mRNA expression levels of interleukin
(IL)-6 and tumor necrosis factor (TNF)-α were hardly de-
tectable after either treatment (< 100 copies/105 copies
ATP5o). mRNA expression of IL-18 and of the transcrip-
tion factor signal transducer and activator of transcription
3 (STAT3) was higher (≥ 5000 copies/105 copies ATP5o)
but still relatively low. EPA + DHA supplementation had
no impact on any of these levels (changes between −15
and +26% vs. placebo, all P ≥ 0.73). Despite these low
levels of expression and the lack of change with EPA +
DHA supplementation, treatment-induced variations in
mRNA STAT3 levels (EPA + DHA vs. placebo) were cor-
related with concurrent variations in mRNA expression of
IL-6 (r = 0.55; P = 0.06), IL-18 (r = 0.64; P = 0.03), and
TNF-α (r = 0.67; P = 0.02).
Discussion
To the best of our knowledge, this study is the first to
assess the impact of EPA + DHA supplementation onTable 3 Inflammatory gene expression in duodenal tissue
after EPA + DHA and placebo supplementation in 12 men
with type 2 diabetes
Placebo EPA + DHA
Difference P
mRNA copies/105 copies ATP5o
IL-6 8 (9) 10 (3) 2 0.77
TNF-α 109 (51) 93 (50) −16 0.75
IL-18 5226 (3552) 5398 (1486) 172 0.73
STAT3 4637 (1723) 4646 (1437) 9 0.91
Data are expressed as median and interquartile range in parentheses. P values
were calculated using Wilcoxon matched-pairs signed-rank tests.
Abbreviations: ATP5o, ATP synthase O subunit; DHA, docosahexaenoic acid;
EPA, eicosapentaenoic acid; IL, interleukin; mRNA, messenger ribonucleic acid;
STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis
factor α.
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sues of obese patients with type 2 diabetes.
Our results first showed that the expression of inflam-
matory genes in duodenal tissues of obese men with type
2 diabetes is relatively low, particularly in the case of
IL-6 and TNF-α. This suggests that inflammation at the
level of duodenal cells per se may not play a significant
role in modulating chronic low-grade inflammation in
obese diabetic patients. As reviewed by Ding and Lund
[4], very little is known on the crosstalk between the in-
testine and adipose tissue in fostering chronic inflamma-
tion. In the case of Crohn’s disease, the extent of
inflammation and cellular damage has been correlated
with the accrual of mesenteric fat around the intestine
(so-called “creeping” fat) [17]. As is the case with
abdominal fat, mesenteric fat is characterized by infil-
tration with immune cells and increased levels of pro-
inflammatory cytokines such as IL-6 and TNF-α [18].
The duodenal biopsy procedure in the present study col-
lected basolateral cells and not cellular material from the
outer surface of the intestine where mesenteric fat would
be found. Thus, our study cannot resolve the possibility
that mesenteric fat expresses pro-inflammatory genes in
type 2 diabetes.
Our study also suggests that 3 g/d EPA + DHA supple-
mentation has no impact on duodenal cells gene expres-
sion of pro-inflammatory cytokines and of transcription
factor STAT3 compared with a placebo. Previous studies
in animal models have shown that LCn-3PUFA from fish
oil down-regulate the small intestine and gut-associated
lymphoid tissue expression of inflammatory mediators
(interferon-γ, chemokines) [19,20]. Other recent studies in
cell culture and animal models also suggest that LCn-
3PUFA down-regulate inflammatory gene expression by
modifying the activity of transcription factors such as
nuclear factor-κB and peroxisome proliferator-activated
receptor-γ, which are expressed in the gastrointestinal
tract [21]. The lack of effect of LCn-3PUFA supplementa-
tion on mRNA expression of pro-inflammatory cytokines
and of transcription factor STAT3 in duodenal tissues of
obese patients with type 2 diabetes in the present study is
most likely attributable to the fact that gene expression
was extremely low and therefore unlikely to be further
modified. However, consistent with our results, a study
performed in 242 human subjects by Pot et al. [22] has
shown that concentrations of local markers of inflamma-
tion measured in biopsy samples of the colon were un-
affected by consumption of oily fish, which represents a
naturally occurring source of EPA + DHA.
A limitation that needs to be pointed out is the limited
number of subjects which yielded limited statistical
power to detect treatment differences in gene expres-
sion. However, mRNA expression levels of inflammatory
genes were very low in most cases, and it is unlikely thatsuch numbers would have changed with a larger sample
size. The use of a randomized crossover design is
strength and the long intervention and washout periods
have limited the possibility of a carry-over effect of the
LCn-3PUFA supplementation. Analyses of plasma fatty
acid profiles following placebo and EPA + DHA supple-
mentation confirmed compliance to treatments.
In summary, we believe this is the first study
suggesting that gene expression of pro-inflammatory cy-
tokines in duodenal tissues from obese patients with
type 2 diabetes is very low and not affected by EPA +
DHA supplementation. Further studies will be needed to
investigate if inflammatory gene expression in other tis-
sues surrounding the intestine such as mesenteric fat is
modulated by EPA + DHA supplementation.
Additional file
Additional file 1: Details on RNA quantification and quantitative real-
time PCR. This file provides complete details on RNA quantification and
quantitative real-time PCR performed in the present study and describes
primer sets used in quantitative real-time PCR from duodenal biopsies.
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